BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta
BioMarin $BMRN may have lost big on their expensive and high-profile bid to get an OK for a troubled Duchenne muscular dystrophy drug, but the West Coast biotech is getting a consolation prize from Sarepta — the big winner so far in the US with its marketed drug Exondys 51.
Sarepta $SRPT is paying BioMarin $35 million to settle their scrap over rights to exon-skipping tech, reserving some 5% and 8% royalty streams for certain exon-skipping therapies. And new Sarepta CEO Doug Ingram lauded the fact that the biotech now has “worldwide freedom” to operate on a drug that it wholly controls.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.